Immune tolerance: A synopsis of the international experience

Haemophilia

Volumn 4, Issue 4, 1998, Pages 568-573

  Di Michele, D M ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Factor IX; Factor VIII; Haemophilia; Immune tolerance; Inhibitors; Registry

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 INHIBITOR;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG PURITY; HEALTH CARE COST; HEMOPHILIA; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MORBIDITY; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037710764     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440568.x     Document Type: Conference Paper

References (28)

1. Ehrenforth S, Kreutz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Briët E, Reisner HM, Roberts HR. Inhibitors in Christmas disease. Prog Clin Biol Res 1984; 150: 123-9.
3. Aledort LM, Cohen M, Hilgartner M, Lipton R. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources. Prog Clin Biol Res 1984; 150: 353-65.
4. Brackmann HH, Gormsen J. Massive factor VIII infusion in a haemphiliac with factor VIII inhibitor, high responder (letter). Lancet 1977; 2 (8044): 933.
5. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
6. Oldenburg J, Brackmann HH. The "Bonn protocol" - update. Vox Sang 1998; in press.
7. Aznar JA, Jorquera JI, Peiro A, et al. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A. Thromb Haemost 1984; 51: 217-21.
8. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-8.
9. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988; 318: 947-50.
10. Sultan Y, Maisonneuve P, Sylvestre R. Plasma exchange in the treatment of hemophiliacs with antibodies to factor VIII. In: Mariani G, Russo MA, Mandelli F, eds. Activated Prothrombin Complex Concentrates. New York: 1982.
11. Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE. Anti-idiotypic suppressing of autoantibodies to Factor VIII (anti-haemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8.
12. Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 381-7.
13. Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A - sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res 1984; 150: 225-41.
14. Freiburghaus C. The "Malmö protocol" - update. Vox Sang 1998; in press.
15. Gribble TJ, Jones JE, Chappelle JA, Vaughan LJ, Friedman KD. Continuous infusion of factor VIII (F-VIII) as part of an immune tolerance induction program. Thromb Haemost 1995; 73: 1024A.
16. van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsvedin-Visset EJM, Sixma JJ. Disappearance of factor VIII:C antibodies in patients with haemophilia upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291-7.
17. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86(3): 983-88.
18. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
19. Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PBA. Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood 1990; 76(5): 882-6.
20. Kreutz W, Mentzer D, Auerswald G et al. Successful immune tolerance therapy of FVIII-inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia 1966; 2 (Suppl 1): 19A.
21. Kroner B. Comparison of the immune tolerance registries. Vox Sang 1998; in press.
22. Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Pro Natl Acad Sci USA 1986; 83: 9169-73.
23. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia. Principal results from the international registry. Thromb Haemost 1994; 72(1): 155-8.
24. Mariani G. The international immune tolerance registry - 1997 update. Vox Sang 1998; in press.
25. DiMichele DM, Kroner BL and the ISTH Factor VIII/IX Subcommittee. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-1997): Current practice implications. Blood 1997; 90 (Suppl 1): 156A.
26. Lenk H. The German national immune tolerance registry - 1997 Update. Vox Sang 1998; in press.
27. Warrier I, Ewenstein BM, Koerper M, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. Am J Pediatr Hematol Oncol 1997; 19(1): 23-7.
28. Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B (letter). Blood 1997; 89(3): 1115-6.